A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

Also called NCT01814748

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 203 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01814748
  • EudraCT 2012-004303-12
Other papers using this trial's data
  • Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds Clinical therapeutics, 2017-10 DOI, PubMed 28923291

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01814748. Randomized; double masking; primary purpose treatment. Start 2013-05-03 (actual); primary completion 2015-09-14 (actual). Results posted on 2016-07-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
Condition
Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Placebo to omarigliptin
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01814748
Content hash
d943d0d9eb3c6669bdf75f949e9286cf9ee64849fa825c21f7aee62786859c0d